比美奇珠单抗治疗中轴型脊柱关节炎2年患者报告结局持续改善
基于BE MOBILE 1和2两项3期研究及其开放标签扩展,评估比美奇珠单抗对中轴型脊柱关节炎患者报告症状、功能和健康相关生活质量的影响。从第16周起全部患者接受比美奇珠单抗160 mg每4周皮下注射,至第104周脊柱疼痛、晨僵、疲劳、睡眠、身体功能和HRQoL均显示持续改善。
要点
- 第104周脊柱总疼痛较基线变化-4.3,夜间脊柱疼痛-4.3,晨僵-4.3。
- 第104周疲劳BASDAI Q1较基线变化-3.4,FACIT-Fatigue较基线变化+9.9。
- 第104周SF-36 PCS较基线变化+12.4,ASQoL较基线变化-5.6。
核心结论
- 比美奇珠单抗治疗使中轴型脊柱关节炎全疾病谱患者报告症状及其影响在2年内持续改善。
研究设计与样本
- BE MOBILE 1(非放射学中轴型脊柱关节炎)和BE MOBILE 2(放射学中轴型脊柱关节炎)包括16周双盲安慰剂对照期和36周维持期。
- 从第16周起全部患者接受比美奇珠单抗160 mg每4周皮下注射。
- 第52周符合条件的患者可进入开放标签扩展BE MOVING并继续比美奇珠单抗治疗。
- 共494/586(84.3%)患者在周52进入BE MOVING,456例完成第104周。
主要发现
- 第104周脊柱总疼痛较基线变化-4.3,夜间脊柱疼痛较基线变化-4.3,晨僵较基线变化-4.3。
- 第104周疲劳BASDAI Q1较基线变化-3.4,FACIT-Fatigue较基线变化+9.9。
- 第104周超过半数患者报告脊柱总疼痛和夜间脊柱疼痛评分≤3。
- 第104周睡眠MOS-Sleep Scale较基线变化+10.2,身体功能BASFI较基线变化-2.9。
- 第104周HRQoL中SF-36 PCS较基线变化+12.4,ASQoL较基线变化-5.6。
关键数值与推荐
- 脊柱疼痛采用0(无痛)至10(最痛)数字评定量表评估。
- 晨僵采用BASDAI第5/6题平均值评估。
- 疲劳采用BASDAI第1题和FACIT-Fatigue子量表评估。
- 睡眠质量采用MOS Sleep Scale Index II评估。
- 身体功能采用BASFI评估,HRQoL采用SF-36 PCS/MCS和ASQoL问卷评估。
临床怎么用
- 比美奇珠单抗160 mg每4周皮下注射在中轴型脊柱关节炎患者中至第104周持续改善患者报告的症状、功能和HRQoL。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3 studies and their open-label extension. METHODS: BE MOBILE 1 (non-radiographic-axSpA) and 2 (radiographic-axSpA) comprised 16-week double-blind placebo-controlled and 36-week maintenance periods. From week 16, all patients received subcutaneous bimekizumab 160 mg every 4 weeks. At week 52, eligible patients could enrol in the open-label extension BE MOVING and continue bimekizumab treatment. Spinal pain (rated on a numerical rating scale from 0 (no pain) to 10 (maximum pain)), morning stiffness (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) average of Q5/6), fatigue (BASDAI Q1; Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue subscale), sleep quality (Medical Outcomes Study (MOS) Sleep Scale Index II), physical function (Bath Ankylosing Spondylitis Functional Index (BASFI)) and HRQoL (36-Item Short Form Survey (SF-36) physical component summary (PCS)/mental component summary (MCS); Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire) were reported to week 104. RESULTS: In total, 494/586 (84.3%) patients entered BE MOVING at week 52; 456 completed week 104. Patients reported substantial changes from baseline to week 104 in total spinal pain (-4.3), nocturnal spinal pain (-4.3), morning stiffness (-4.3) and fatigue (BASDAI Q1: -3.4; FACIT-Fatigue: +9.9). Over half reported total and nocturnal spinal pain scores ≤3 at week 104. Similar improvements to week 104 were shown in sleep (MOS-Sleep Scale: +10.2), physical function (BASFI: -2.9) and HRQoL (SF-36 PCS: +12.4; ASQoL: -5.6). CONCLUSIONS: Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms and their impacts across the full disease spectrum of axSpA over 2 years, underscoring its long-term potential for improving patients' daily lives. TRIAL REGISTRATION NUMBERS: NCT03928704, NCT03928743, NCT04436640.
引用
- Marzo-Ortega H, Navarro-Compan V, Dubreuil M, et al. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025. PMID: 41314667. doi:10.1136/rmdopen-2025-006013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。